BSO is indicated for various reasons including treatment of ovarian cancer, benign ovarian conditions affecting both ovaries, for example, endometriosis, ovarian cancer risk reduction in high-risk women (eg, BRCA1 and BRCA2 PV carriers)20 or for OFS in patients with breast cancer with ER-positive tumours.6 This evidence concerns the gene BRCA2 and endometriosis.